RenovoRx, Inc.

About RenovoRx, Inc.

RenovoRx is a life science company focused on developing innovative targeted oncology therapies using a local drug-delivery platform. Their mission is to improve therapeutic outcomes for cancer patients by delivering therapies directly to tumor sites, aiming to enhance safety, tolerance, and efficacy.

Products & Services

TAMP (Trans-Arterial Micro-Perfusion) Therapy Platform:A patented technology designed for precise therapeutic delivery across the arterial wall near tumor sites, potentially minimizing toxicities compared to systemic IV therapy. It is being investigated for treating locally advanced pancreatic cancer (LAPC).

RenovoCath:An FDA-cleared device used for temporary vessel occlusion and delivery of fluids, including chemotherapeutic drugs, to selected sites in the peripheral vascular system. It is a key component of the TAMP platform.

Phase III TIGeR-PaC Clinical Trial:An ongoing randomized multi-center study evaluating the TAMP therapy platform for treating locally advanced pancreatic cancer (LAPC) by comparing intra-arterial chemotherapy delivery with standard systemic administration.

RenovoCath® (FDA-cleared drug-delivery device)

IAG (investigational intra-arterial gemcitabine combination product)

Specialties

Targeted Oncology Therapies Local Drug-Delivery Platforms Pancreatic Cancer Treatment Trans-Arterial Micro-Perfusion (TAMP) Technology Targeted oncology therapies TAMP™ therapy platform Trans-arterial drug delivery for pancreatic cancer

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 10000000 MR: - FA: approximately $10 million FAN: 10000000	D: 2026-03-20 FD: 2026-03-20	5 investors
2	RT: Private Placement T: - FT: Private Placement	A: 10000000 MR: - FA: approximately $10 million FAN: 10000000	D: 2026-03-18 FD: 2026-03-18	3 investors
3	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 12100000 MR: - FA: 12.1 million FAN: 12100000	D: 2025-02-11 FD: 2025-02-11	2 investors
4	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 12100000 MR: - FA: 12.1 million FAN: 12100000	D: 2025-02-06 FD: 2025-02-06	1 investors
5	RT: Private Placement T: - FT: Private Placement	A: 11100000 MR: - FA: $11.1 million FAN: 11100000	D: 2024-04-15 FD: 2024-04-15	-
6	RT: Private Placement T: - FT: Private Placement	A: 11100000 MR: - FA: $11.1 million FAN: 11100000	D: 2024-04-08 FD: 2024-04-08	-
7	RT: Private Placement T: - FT: Private Placement	A: 6100000 MR: - FA: approximately $6.1 million FAN: 6100000	D: 2024-01-29 FD: 2024-01-29	3 investors
8	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 5000000 MR: - FA: approximately $5 million FAN: 5000000	D: 2023-03-30 FD: 2023-03-30	1 investors

Private Placement Latest

2026-03-20

$10.0M

5 investors (Pro only)

Private Placement 2026-03-18

$10.0M

Underwritten Public Offering 2025-02-11

$12.1M

View 7 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Shaun R. Bagai

Chief Executive Officer

R

Ramtin Agah

Chief Medical Officer, Founder

M

Mark Voll

Chief Financial Officer

L

Leesa Gentry

Chief Clinical Officer

R

Robert Strasser

VP of Operations and R&D

R

Ronald B. Kocak

Vice President of Finance and Controller

View 21 more team members with Pro

Unlock Full Team Directory

Recent News

RenovoRx, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised